GC Cell지씨셀

GC Cell's trailing revenue is still about ₩162B, but losses are deep and the shares have fallen 38% over the past year.

GC Cell is a Korean cell therapy developer with services that include specimen testing, cord blood banking, cold-chain logistics and contract manufacturing. Over the last twelve months to H1 2026 it posted revenue of ₩162B, an operating loss of ₩10.8B and a net loss of ₩246B, with a net margin of -152.1%. The data does not include any forecasts or analyst views.

What stands out

• Revenue has fallen from ₩236B in 2022 to ₩166B in 2025, and the company moved from operating profit in 2021-2023 to operating losses since 2024.
• The 2025 net loss of ₩273B is far larger than the operating loss of ₩14B, and the filed data does not explain the gap.
• Borrowings stand at ₩82B against cash of ₩1.4B, and liabilities are 77% of equity.
• The share price is ₩12,960, down 37.7% over one year and near the 52-week low of ₩11,610; the price-to-book ratio is 1.1 and no dividend is paid.
• Foreign ownership fell from 3.3% to 2.9% over about 60 days, while retail investors were net sellers over the last 20 days.

What to watch

• The full-year 2026 results and the H1 2026 half-year report, which will show whether losses are narrowing.
• News on the AB-101 phase 3 trial and the Turkey market talks, which the headlines mention but the data does not detail.
• Insider shareholding reports and the management matter filed on 20 July 2026, whose content is not in the data.